248 related articles for article (PubMed ID: 25973023)
1. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.
Chin SY; Wu PR; Shih YH; Yeh CM; Lee WR; Shen SC; Yeh KT; Jiang MC; Tseng JT
Int J Clin Exp Pathol; 2015; 8(2):1393-401. PubMed ID: 25973023
[TBL] [Abstract][Full Text] [Related]
2. CSE1L Links cAMP/PKA and Ras/ERK pathways and regulates the expressions and phosphorylations of ERK1/2, CREB, and MITF in melanoma cells.
Lee WR; Shen SC; Wu PR; Chou CL; Shih YH; Yeh CM; Yeh KT; Jiang MC
Mol Carcinog; 2016 Nov; 55(11):1542-1552. PubMed ID: 26331446
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.
Slipicevic A; Holm R; Emilsen E; Ree Rosnes AK; Welch DR; Mælandsmo GM; Flørenes VA
BMC Cancer; 2012 Feb; 12():73. PubMed ID: 22356677
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
5. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
6. Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Lee WR; Shen SC; Shih YH; Chou CL; Tseng JT; Chin SY; Liu KH; Chen YC; Jiang MC
J Transl Med; 2015 Jun; 13():191. PubMed ID: 26070816
[TBL] [Abstract][Full Text] [Related]
7. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic phosphorylated ERK1/2 expression in patients with melanoma is associated with tumor stage and metastasis.
Tseng YS; Wu PR; Lu JW; Wang YF; Yeh KT; Lin SH
Biotech Histochem; 2022 Feb; 97(2):118-125. PubMed ID: 33902381
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas.
Chang CC; Tai CJ; Su TC; Shen KH; Lin SH; Yeh CM; Yeh KT; Lin YM; Jiang MC
Ann Diagn Pathol; 2012 Oct; 16(5):362-8. PubMed ID: 22476051
[TBL] [Abstract][Full Text] [Related]
11. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
12. AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells.
Lorenzato A; Biolatti M; Delogu G; Capobianco G; Farace C; Dessole S; Cossu A; Tanda F; Madeddu R; Olivero M; Di Renzo MF
Exp Cell Res; 2013 Oct; 319(17):2627-36. PubMed ID: 23948303
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
[TBL] [Abstract][Full Text] [Related]
14. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of COX-2 protein expression in melanocytic nevi in children].
Kubus M; Andrzejewska E; Nejc D; Kobos J; Taran K
Pol Merkur Lekarski; 2013 Aug; 35(206):82-4. PubMed ID: 24052986
[TBL] [Abstract][Full Text] [Related]
16. Nuclear and cytoplasmic features in the diagnosis of Clark's nevi.
Valdebran M; Bandino J; Elbendary A; Gad A; Arudra KC; de Feraudy S; Elston DM
J Cutan Pathol; 2018 Mar; 45(3):204-207. PubMed ID: 29193203
[TBL] [Abstract][Full Text] [Related]
17. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
18. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
19. Potential diagnostic significance of HSP90, ACS/TMS1, and L-plastin in the identification of melanoma.
Strickler AG; Vasquez JG; Yates N; Ho J
Melanoma Res; 2014 Dec; 24(6):535-44. PubMed ID: 25191796
[TBL] [Abstract][Full Text] [Related]
20. Correlations between cytoplasmic CSE1L in neoplastic colorectal glands and depth of tumor penetration and cancer stage.
Tai CJ; Su TC; Jiang MC; Chen HC; Shen SC; Lee WR; Liao CF; Chen YC; Lin SH; Li LT; Shen KH; Yeh CM; Yeh KT; Lee CH; Shih HY; Chang CC
J Transl Med; 2013 Jan; 11():29. PubMed ID: 23369209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
